| 2026-02-24 |
20-F |
20-F |
View Document |
| 2026-02-24 |
6-K |
FORM 6-K |
View Document |
| 2026-02-24 |
6-K |
ANNUAL FINANCIAL REPORT |
View Document |
| 2026-02-24 |
6-K |
DIRECTORATE CHANGE |
View Document |
| 2026-02-20 |
6-K |
FIXED-DURATION CALQUENCE COMBO APPROVED IN US |
View Document |
| 2026-02-10 |
6-K |
FINAL RESULTS |
View Document |
| 2026-02-06 |
SCHEDULE 13G/A |
|
View Document |
| 2026-02-06 |
SCHEDULE 13D/A |
|
View Document |
| 2026-02-03 |
6-K |
UPDATE ON SAPHNELO SUBCUTANEOUS ADMINISTRATION |
View Document |
| 2026-02-02 |
S-8 |
FORM S-8 |
View Document |
| 2026-02-02 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2026-02-02 |
6-K |
IMFINZI RECOMMENDED IN EU FOR EARLY GASTRIC CANCER |
View Document |
| 2026-02-02 |
6-K |
ASTRAZENECA BEGINS TRADING ON NYSE |
View Document |
| 2026-01-30 |
25 |
FORM 25 |
View Document |
| 2026-01-30 |
6-K |
ASTRAZENECA AGREES OBESITY AND T2D DEAL WITH CSPC |
View Document |
| 2026-01-29 |
6-K |
ASTRAZENECA INVESTS $15BN IN CHINA THROUGH 2030 |
View Document |
| 2026-01-22 |
CERT |
NYSE CERTIFICATION |
View Document |
| 2026-01-22 |
8-A12B |
8-A12B |
View Document |
| 2026-01-22 |
CERT |
NYSE CERTIFICATION |
View Document |
| 2026-01-22 |
8-A12B |
8-A12B |
View Document |
| 2026-01-20 |
6-K |
ASTRAZENECA TO COMPLETE DIRECT LISTING ON NYSE |
View Document |
| 2026-01-08 |
6-K |
AZN NEW HEAD OF INVESTOR RELATIONS JORIS SILON |
View Document |
| 2026-01-02 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2025-12-22 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2025-12-22 |
6-K |
ENHERTU GRANTED BTD FOR POST-NEOADJUVANT EARLY BC |
View Document |
| 2025-12-22 |
6-K |
UPDATE ON LATIFY PHASE III TRIAL OF CERALASERTIB |
View Document |
| 2025-12-19 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2025-12-16 |
6-K |
SUBCUTANEOUS SAPHNELO APPROVED IN EU |
View Document |
| 2025-12-16 |
6-K |
ENHERTU APPROVED IN US FOR 1L HER2+ METASTATIC BC |
View Document |
| 2025-12-04 |
6-K |
HOLDING(S) IN COMPANY |
View Document |
| 2025-12-01 |
6-K |
BLOCK LISTING INTERIM REVIEW |
View Document |
| 2025-12-01 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2025-11-26 |
6-K |
IMFINZI APPROVED IN US FOR EARLY GASTRIC CANCER |
View Document |
| 2025-11-24 |
6-K |
ASTRAZENECA MANUFACTURING INVESTMENT IN MARYLAND |
View Document |
| 2025-11-20 |
6-K |
KOSELUGO (SELUMETINIB) APPROVED IN THE US |
View Document |
| 2025-11-17 |
6-K |
HOLDING(S) IN COMPANY |
View Document |
| 2025-11-14 |
25-NSE |
|
View Document |
| 2025-11-14 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2025-11-12 |
144 |
|
View Document |
| 2025-11-10 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2025-11-06 |
6-K |
9M AND Q3 2025 RESULTS |
View Document |
| 2025-11-03 |
6-K |
RESULT OF GENERAL MEETING |
View Document |
| 2025-11-03 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2025-11-03 |
6-K |
FORM 6-K |
View Document |
| 2025-10-28 |
6-K |
DIRECTOR DECLARATION |
View Document |
| 2025-10-28 |
6-K |
KOSELUGO (SELUMETINIB) APPROVED IN THE EU |
View Document |
| 2025-10-22 |
6-K |
TEZSPIRE APPROVED IN EU FOR CRSWNP |
View Document |
| 2025-10-20 |
6-K |
US FDA APPROVES TEZSPIRE IN CRSWNP |
View Document |
| 2025-10-20 |
6-K |
POSITIVE CHMP OPINION FOR SUBCUTANEOUS SAPHNELO |
View Document |
| 2025-10-14 |
6-K |
AGREEMENT WITH US GOVT TO LOWER MEDICINE PRICES |
View Document |
| 2025-10-07 |
6-K |
BAXDROSTAT MET PRIMARY ENDPOINT IN BAX24 PH3 TRIAL |
View Document |
| 2025-10-06 |
6-K |
DATROWAY IMPROVED OS AND PFS IN TROPION-BREAST02 |
View Document |
| 2025-10-01 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2025-09-29 |
6-K |
ENHERTU IMPROVED IDFS IN EARLY BC IN DB-05 |
View Document |
| 2025-09-29 |
6-K |
AZN HARMONISES LISTING STRUCTURE |
View Document |
| 2025-09-29 |
6-K |
6-K |
View Document |
| 2025-09-25 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2025-09-22 |
6-K |
KOSELUGO RECOMMENDED FOR EU APPROVAL |
View Document |
| 2025-09-22 |
6-K |
TEZSPIRE RECOMMENDED FOR APPROVAL IN EU FOR CRSWNP |
View Document |
| 2025-09-17 |
6-K |
SAPHNELO MET PRIMARY ENDPOINT IN TULIP-SC |
View Document |
| 2025-09-17 |
6-K |
UPDATE ON RESOLUTE PHASE III TRIAL |
View Document |
| 2025-09-02 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2025-08-28 |
6-K |
HOLDING(S) IN COMPANY |
View Document |
| 2025-08-26 |
6-K |
HOLDING(S) IN COMPANY |
View Document |
| 2025-08-21 |
6-K |
HOLDING(S) IN COMPANY |
View Document |
| 2025-08-18 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2025-08-15 |
6-K |
HOLDING(S) IN COMPANY |
View Document |
| 2025-08-12 |
6-K |
HOLDING(S) IN COMPANY |
View Document |
| 2025-08-01 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2025-07-29 |
6-K |
FORM 6-K |
View Document |
| 2025-07-24 |
6-K |
GEFURULIMAB NANOBODY MET PHASE III ENDPOINTS |
View Document |
| 2025-07-22 |
6-K |
ASTRAZENECA PLANS TO INVEST $50BN IN THE US |
View Document |
| 2025-07-16 |
6-K |
UPDATE ON ANSELAMIMAB IN AL AMYLOIDOSIS |
View Document |
| 2025-07-14 |
6-K |
BAXDROSTAT MET PRIMARY ENDPT IN BAXHTN PHIII TRIAL |
View Document |
| 2025-07-07 |
6-K |
IMFINZI APPROVED IN THE EU FOR BLADDER CANCER |
View Document |
| 2025-07-01 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2025-06-26 |
11-K |
FORM 11-K |
View Document |
| 2025-06-24 |
6-K |
DATROWAY APPROVED IN US FOR EGFRM LUNG CANCER |
View Document |
| 2025-06-13 |
6-K |
ASTRAZENECA ENTERS INTO COLLABORATION WITH CSPC |
View Document |
| 2025-06-12 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2025-06-06 |
6-K |
FIXED-DURATION CALQUENCE APPROVED IN EU FOR 1L CLL |
View Document |
| 2025-06-02 |
6-K |
BLOCK LISTING INTERIM REVIEW |
View Document |
| 2025-06-02 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2025-05-27 |
6-K |
IMFINZI RECOMMENDED IN EU FOR BLADDER CANCER |
View Document |
| 2025-05-23 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2025-05-21 |
6-K |
DIRECTOR DECLARATION |
View Document |
| 2025-05-20 |
6-K |
ACQUISITION OF ESOBIOTEC COMPLETED |
View Document |
| 2025-05-09 |
6-K |
IMFINZI IMPROVED DFS IN EARLY BLADDER CANCER |
View Document |
| 2025-05-07 |
6-K |
ENHERTU IMPROVED PCR IN EARLY-STAGE BREAST CANCER |
View Document |
| 2025-05-06 |
6-K |
CALQUENCE COMBINATION APPROVED IN EU FOR 1L MCL |
View Document |
| 2025-05-02 |
6-K |
BREZTRI MET PRIMARY ENDPOINTS IN PH3 ASTHMA TRIALS |
View Document |
| 2025-05-01 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2025-05-01 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2025-04-29 |
6-K |
FIXED-DURATION CALQUENCE RECOMMENDED IN EU FOR CLL |
View Document |
| 2025-04-29 |
6-K |
UPDATE ON CAPITELLO-280 PHASE III TRIAL |
View Document |
| 2025-04-29 |
6-K |
1ST QUARTER RESULTS |
View Document |
| 2025-04-23 |
SCHEDULE 13G/A |
|
View Document |
| 2025-04-22 |
6-K |
ENHERTU COMBINATION IMPROVED PFS IN 1L HER2+ MBC |
View Document |
| 2025-04-11 |
6-K |
RESULT OF AGM |
View Document |
| 2025-04-10 |
SCHEDULE 13G/A |
|
View Document |
